Alterity secures fda alignment for ATH434 phase 3 pathway

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Alterity Therapeutics received official End-of-Phase 2 meeting minutes from the U.S. Food and Drug Administration confirming a registrational pathway for ATH434 in multiple system atrophy.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE